Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 5, 2000, Pages 418-424

  Kazatchkine, Michel D ^a   Van, P Ngo ^b   Costagliola, D ^c   Mohammed, A Si ^a   Ledeine, J M ^b   Troccaz, M ^b   Belec, L ^a  

^a HÔPITAL BROUSSAIS   (France)

^b BRISTOL MYERS SQUIBB   (United States)

^c INSERM   (France)

Author keywords

Combination therapy; Didanosine; Once daily dosing; Twice daily dosing

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; VIRUS LOAD;

EID: 0034662734     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200008150-00003     Document Type: Article

References (21)

1. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: Results of a phase I trial
2. Didanosine in the treatment of AIDS and AIDS-related complex: A critical appraisal of the dose and frequency of administration
3. 175 Study Team: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
4. STADI: Sustained efficacy of once-daily administration of didanosine in combination with stavudine
5. Once daily administration of ddI in combination with d4T among naive HIV infected patients
6. Comparison of once- and twice-daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection
7. Virologic and immunologic responses to once-daily dosing of didanosine in combination with stavudine
8. Ritonavir, stavudine (d4T), didanosine (ddI) as a triple combination treatment in antiretroviral-naive patients
9. Stavudine (d4T), didanosine (ddI) and nelfinavir combination therapy in pretreated HIV-patients: Antiviral effect and safety in an ongoing study
10. Short-term efficacy and safety of ddI and 3TC both once daily plus indinavir BID
11. Nelfinavir, didanosine and stavudine in HIV-infected drug users enrolled in opiate substitution programs at four outpatient clinics: The Zurich Prometheus Study
12. Stavudine-didanosine-nevirapine: A convenient highly active triple combination for first line antiretroviral therapy
13. Efficacy of the combination stavudine (d4T), didanosine (ddI) and nevirapine (NVP) as initial antiretroviral therapy and following treatment with protease inhibitors
14. DDI once daily vs twice daily alone and also with hydroxyurea once daily
15. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxurea, for HIV infection
16. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
17. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee
18. Antiretroviral drug resistance testing in adults with HIV infection
19. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyadenosine
20. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once- and twice-daily dosing in HIV-1 infected individuals
21. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study